Online Only Articles

Ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysis

Department of Haematology, Plymouth University Medical School, UK
Department of Medicine III, Klinikum der Universität München, LMU, Germany
Department of Hematology & Oncology, John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, NJ, USA
Department of Hematology, Oncology and Pneumology, University Medical School of the Johannes Gutenberg-University, Mainz, Germany
Centre for Haemato-Oncology, Barts Cancer Institute, London, UK
Department of Medicine, Washington University, St. Louis, MO, USA
Hematology Department, Hospital Universitario Infanta Leonor, Universidad Complutense, Madrid, Spain
Janssen Research & Development, Raritan, NJ, USA
Janssen Research & Development, Raritan, NJ, USA
Janssen Research & Development, Raritan, NJ, USA
Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Vol. 104 No. 5 (2019): May, 2019 https://doi.org/10.3324/haematol.2018.205229